These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

593 related articles for article (PubMed ID: 28675654)

  • 1. Bioinformatory-assisted analysis of next-generation sequencing data for precision medicine in pancreatic cancer.
    Malgerud L; Lindberg J; Wirta V; Gustafsson-Liljefors M; Karimi M; Moro CF; Stecker K; Picker A; Huelsewig C; Stein M; Bohnert R; Del Chiaro M; Haas SL; Heuchel RL; Permert J; Maeurer MJ; Brock S; Verbeke CS; Engstrand L; Jackson DB; Grönberg H; Löhr JM
    Mol Oncol; 2017 Oct; 11(10):1413-1429. PubMed ID: 28675654
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical Utility of Circulating Tumor DNA for Molecular Assessment and Precision Medicine in Pancreatic Cancer.
    Takai E; Totoki Y; Nakamura H; Kato M; Shibata T; Yachida S
    Adv Exp Med Biol; 2016; 924():13-17. PubMed ID: 27753011
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma.
    Qian Y; Gong Y; Fan Z; Luo G; Huang Q; Deng S; Cheng H; Jin K; Ni Q; Yu X; Liu C
    J Hematol Oncol; 2020 Oct; 13(1):130. PubMed ID: 33008426
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination of KRAS and SMAD4 mutations in formalin-fixed paraffin-embedded tissues as a biomarker for pancreatic cancer.
    Yokose T; Kitago M; Matsuda S; Sasaki Y; Masugi Y; Nakamura Y; Shinoda M; Yagi H; Abe Y; Oshima G; Hori S; Yusuke F; Nakano Y; Endo Y; Abe K; Tokino T; Kitagawa Y
    Cancer Sci; 2020 Jun; 111(6):2174-2182. PubMed ID: 32314446
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Variant Profiling of Candidate Genes in Pancreatic Ductal Adenocarcinoma.
    Huang J; Löhr JM; Nilsson M; Segersvärd R; Matsson H; Verbeke C; Heuchel R; Kere J; Iafrate AJ; Zheng Z; Ye W
    Clin Chem; 2015 Nov; 61(11):1408-16. PubMed ID: 26378065
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of next-generation sequencing on the clinical diagnosis of pancreatic cysts.
    Jones M; Zheng Z; Wang J; Dudley J; Albanese E; Kadayifci A; Dias-Santagata D; Le L; Brugge WR; Fernandez-del Castillo C; Mino-Kenudson M; Iafrate AJ; Pitman MB
    Gastrointest Endosc; 2016 Jan; 83(1):140-8. PubMed ID: 26253016
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutant
    Perets R; Greenberg O; Shentzer T; Semenisty V; Epelbaum R; Bick T; Sarji S; Ben-Izhak O; Sabo E; Hershkovitz D
    Oncologist; 2018 May; 23(5):566-572. PubMed ID: 29371474
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mutation analysis by deep sequencing of pancreatic juice from patients with pancreatic ductal adenocarcinoma.
    Choi MH; Mejlænder-Andersen E; Manueldas S; El Jellas K; Steine SJ; Tjensvoll K; Sætran HA; Knappskog S; Hoem D; Nordgård O; Hovland R; Molven A
    BMC Cancer; 2019 Jan; 19(1):11. PubMed ID: 30611220
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel hotspot and rare somatic mutation p.A138V, at TP53 is associated with poor survival of pancreatic ductal and periampullary adenocarcinoma patients.
    Saha G; Singh R; Mandal A; Das S; Chattopadhyay E; Panja P; Roy P; DeSarkar N; Gulati S; Ghatak S; Ghosh S; Banerjee S; Roy B; Ghosh S; Chaudhuri D; Arora N; Biswas NK; Sikdar N
    Mol Med; 2020 Jun; 26(1):59. PubMed ID: 32552660
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeted next generation sequencing of endoscopic ultrasound acquired cytology from ampullary and pancreatic adenocarcinoma has the potential to aid patient stratification for optimal therapy selection.
    Gleeson FC; Kerr SE; Kipp BR; Voss JS; Minot DM; Tu ZJ; Henry MR; Graham RP; Vasmatzis G; Cheville JC; Lazaridis KN; Levy MJ
    Oncotarget; 2016 Aug; 7(34):54526-54536. PubMed ID: 27203738
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Profiling of conditionally reprogrammed cell lines for in vitro chemotherapy response prediction of pancreatic cancer.
    Lee HS; Kim E; Lee J; Park SJ; Hwang HK; Park CH; Jo SY; Kang CM; Hong SM; Kang H; Jo JH; Cho IR; Chung MJ; Park JY; Park SW; Song SY; Han JM; Kim S; Bang S
    EBioMedicine; 2021 Mar; 65():103218. PubMed ID: 33639403
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mutations in key driver genes of pancreatic cancer: molecularly targeted therapies and other clinical implications.
    Hu HF; Ye Z; Qin Y; Xu XW; Yu XJ; Zhuo QF; Ji SR
    Acta Pharmacol Sin; 2021 Nov; 42(11):1725-1741. PubMed ID: 33574569
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comprehensive Analysis of Somatic Mutations in Driver Genes of Resected Pancreatic Ductal Adenocarcinoma Reveals KRAS G12D and Mutant TP53 Combination as an Independent Predictor of Clinical Outcome.
    Shoucair S; Habib JR; Pu N; Kinny-Köster B; van Ooston AF; Javed AA; Lafaro KJ; He J; Wolfgang CL; Yu J
    Ann Surg Oncol; 2022 Apr; 29(4):2720-2731. PubMed ID: 34792696
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Precision medicine for pancreatic cancer: characterizing the clinicogenomic landscape and outcomes of KRAS G12C-mutated disease.
    Keane F; Chou JF; Walch H; Schoenfeld J; Singhal A; Cowzer D; Harrold E; O'Connor CA; Park W; Varghese A; El Dika I; Balogun F; Yu KH; Capanu M; Schultz N; Yaeger R; O'Reilly EM
    J Natl Cancer Inst; 2024 Sep; 116(9):1429-1438. PubMed ID: 38702822
    [TBL] [Abstract][Full Text] [Related]  

  • 15.
    Sinn M; Sinn BV; Treue D; Keilholz U; Damm F; Schmuck R; Lohneis P; Klauschen F; Striefler JK; Bahra M; Bläker H; Bischoff S; Pelzer U; Oettle H; Riess H; Budczies J; Denkert C
    Clin Cancer Res; 2020 Jul; 26(14):3732-3739. PubMed ID: 32234756
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Next generation sequencing of pancreatic ductal adenocarcinoma: right or wrong?
    Connor AA; Gallinger S
    Expert Rev Gastroenterol Hepatol; 2017 Jul; 11(7):683-694. PubMed ID: 28460572
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pancreatic adenocarcinoma with a germline PTEN p.Arg234Gln mutation.
    Uemura S; Matsubayashi H; Kiyozumi Y; Uesaka K; Yamamoto Y; Sasaki K; Abe M; Urakami K; Kusuhara M; Yamaguchi K
    Fam Cancer; 2018 Apr; 17(2):255-259. PubMed ID: 28755079
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Utility of Assessing the Number of Mutated KRAS, CDKN2A, TP53, and SMAD4 Genes Using a Targeted Deep Sequencing Assay as a Prognostic Biomarker for Pancreatic Cancer.
    Hayashi H; Kohno T; Ueno H; Hiraoka N; Kondo S; Saito M; Shimada Y; Ichikawa H; Kato M; Shibata T; Morizane C; Sakamoto Y; Shimada K; Komatsu Y; Sakamoto N; Okusaka T
    Pancreas; 2017 Mar; 46(3):335-340. PubMed ID: 28099251
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets.
    Witkiewicz AK; McMillan EA; Balaji U; Baek G; Lin WC; Mansour J; Mollaee M; Wagner KU; Koduru P; Yopp A; Choti MA; Yeo CJ; McCue P; White MA; Knudsen ES
    Nat Commun; 2015 Apr; 6():6744. PubMed ID: 25855536
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Building on the clinical applicability of ctDNA analysis in non-metastatic pancreatic ductal adenocarcinoma.
    Labiano I; Huerta AE; Alsina M; Arasanz H; Castro N; Mendaza S; Lecumberri A; Gonzalez-Borja I; Guerrero-Setas D; Patiño-Garcia A; Alkorta-Aranburu G; Hernández-Garcia I; Arrazubi V; Mata E; Gomez D; Viudez A; Vera R
    Sci Rep; 2024 Jul; 14(1):16203. PubMed ID: 39003322
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.